

Webcast: IPO and Public Company Readiness: Alternatives to IPOs: Reverse Mergers and Reg A+

Webcasts | October 22, 2025

Join partners Branden Berns and Stewart McDowell as we continue our discussion on alternatives to IPOs. This recorded one-hour CLE webcast focuses on reverse mergers and Reg A+ offerings as alternative paths to access the public capital markets. Viewers will gain valuable insight into the benefits of (and considerations for) these transaction structures, which can be attractive alternative transactions that lack some of the disadvantages of a traditional IPO. Key topics include:

- Overview of reverse merger transaction structures and legal frameworks
- Identifying the most beneficial transaction for your company
- Recent examples

Related People

[Branden C. Berns](#)

[Stewart McDowell](#)

MCLE CREDIT INFORMATION: This program has been approved for credit in accordance with the requirements of the New York State Continuing Legal Education Board for a maximum of 1.0 credit hour, of which 1.0 credit hour may be applied toward the areas of professional practice requirement. This course is approved for transitional/non-transitional credit. Gibson, Dunn & Crutcher LLP certifies that this activity has been approved for MCLE credit by the State Bar of California in the amount of 1.0 hour. Gibson, Dunn & Crutcher LLP is authorized by the Solicitors Regulation Authority to provide in-house CPD training. This program is approved for CPD credit in the amount of 1.0 hour. Regulated by the Solicitors Regulation Authority (Number 324652). Neither the Connecticut Judicial Branch nor the Commission on Minimum Continuing Legal Education approve or accredit CLE providers or activities. It is the opinion of this provider that this activity qualifies for up to 1 hour toward your annual CLE requirement in Connecticut, including 0 hour(s) of ethics/professionalism. Application for approval is pending with the Colorado, Illinois, Texas, Virginia and Washington State Bars.

PANELISTS: **Branden C. Berns** is a partner in the San Francisco office of Gibson Dunn where he practices in the firm's Transactional Department. He represents leading life sciences companies and investors on a broad range of complex corporate transactions, including mergers and acquisitions, asset sales, spin-offs, joint ventures, PIPEs, as well as a variety of financing transactions, including initial public offerings, secondary equity offerings and venture and growth equity financings. Branden also serves as principal outside counsel for numerous publicly-traded life sciences companies and advises management and boards of directors on corporate law matters, SEC reporting and corporate governance. **Stewart L. McDowell** is a partner in the San Francisco and New York offices of Gibson Dunn where she is Co-Chair of the firm's Capital Markets Practice Group. Stewart represents companies, investors and underwriters in a variety of complex capital markets transactions, including IPOs, convertible and non-convertible debt and preferred equity offerings, PIPEs and liability management transactions. She also represents companies in connection with U.S. and cross-border M&A and strategic investments, SEC reporting, corporate governance and general corporate matters. © 2025 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. Attorney Advertising: These materials were

GIBSON DUNN

prepared for general informational purposes only based on information available at the time of publication and are not intended as, do not constitute, and should not be relied upon as, legal advice or a legal opinion on any specific facts or circumstances. Gibson Dunn (and its affiliates, attorneys, and employees) shall not have any liability in connection with any use of these materials. The sharing of these materials does not establish an attorney-client relationship with the recipient and should not be relied upon as an alternative for advice from qualified counsel. Please note that facts and circumstances may vary, and prior results do not guarantee a similar outcome.

Related Capabilities

[Capital Markets](#)

[Public Companies](#)